Neurocrine Biosciences And Voyager Therapeutics Form Strategic Development And Commercialization Collaboration For Parkinson's Disease And Friedreich's Ataxia; Voyager Receives $165M Upfront, Up To $1.7B In Milestones
Benzinga Newsdesk